The effectiveness of traditional Japanese medicine (Kampo), in combination with pegylated interferon α plus ribavirin for patients with chronic hepatitis C

A pilot study

Mosaburo Kainuma, Norihiro Furusyo, Murata Masayuki, Takeshi Ihara, Hiroaki Ikezaki, Kazuhiro Toyoda, Eiichi Ogawa, Kyoko Okada, Jun Hayashi

Research output: Contribution to journalArticle

Abstract

Background: Kampo medicine has been shown to be useful for reducing the adverse effects of pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV). The study was done to determine if Kampo would have a synergistic effect with PEG-IFNα-2b plus RBV that would improve their effectiveness in the treatment of chronic hepatitis C. Methods: From a total of 51 chronic hepatitis C virus (HCV) patients, 26 received PEG-IFNα-2b plus RBV treatment combined with Kampo medicine (group A) and 25 received only the standard treatment (group B). Group B patients were prescribed a mixture of shimbuto and ninjinto extract to be taken three times a day before meals. Results: The early virological response (EVR) and sustained virological response (SVR) rates were significantly higher in group A than in group B (EVR: 84.6%, 22 of 26 vs 56.0%, 14 of 25, P=0.034: SVR: 76.9%, 20 of 26 vs 48.0%, 12 of 25, P=0.033). 22 of 26 patients in group A (84.6%) and 18 of 25 patients in group B (72.0%) received at least the minimum acceptable dosage (at least 80% or more of the target PEG-IFNα-2b and 60% or more of RBV) during treatment, with no significant between group difference in the rate of SVR. The discontinuation rate was significantly lower in group A, in which no patients discontinued, than in group B (20.0%, 5 of 25) (P=0.023). Conclusions: A mixture of shimbuto and ninjinto reduced the discontinuation rate and improved the treatment efficacy of patients with chronic HCV treated with PEG-IFNα-2b plus RBV.

Original languageEnglish
Pages (from-to)132-139
Number of pages8
JournalJournal of Traditional Medicines
Volume30
Issue number3
DOIs
Publication statusPublished - 2013

Fingerprint

Kampo Medicine
Ribavirin
Traditional Medicine
Chronic Hepatitis C
Interferons
Hepacivirus
Meals
Therapeutics

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine
  • Drug Discovery

Cite this

@article{d5e36d32c9114da3816cae2de607f291,
title = "The effectiveness of traditional Japanese medicine (Kampo), in combination with pegylated interferon α plus ribavirin for patients with chronic hepatitis C: A pilot study",
abstract = "Background: Kampo medicine has been shown to be useful for reducing the adverse effects of pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV). The study was done to determine if Kampo would have a synergistic effect with PEG-IFNα-2b plus RBV that would improve their effectiveness in the treatment of chronic hepatitis C. Methods: From a total of 51 chronic hepatitis C virus (HCV) patients, 26 received PEG-IFNα-2b plus RBV treatment combined with Kampo medicine (group A) and 25 received only the standard treatment (group B). Group B patients were prescribed a mixture of shimbuto and ninjinto extract to be taken three times a day before meals. Results: The early virological response (EVR) and sustained virological response (SVR) rates were significantly higher in group A than in group B (EVR: 84.6{\%}, 22 of 26 vs 56.0{\%}, 14 of 25, P=0.034: SVR: 76.9{\%}, 20 of 26 vs 48.0{\%}, 12 of 25, P=0.033). 22 of 26 patients in group A (84.6{\%}) and 18 of 25 patients in group B (72.0{\%}) received at least the minimum acceptable dosage (at least 80{\%} or more of the target PEG-IFNα-2b and 60{\%} or more of RBV) during treatment, with no significant between group difference in the rate of SVR. The discontinuation rate was significantly lower in group A, in which no patients discontinued, than in group B (20.0{\%}, 5 of 25) (P=0.023). Conclusions: A mixture of shimbuto and ninjinto reduced the discontinuation rate and improved the treatment efficacy of patients with chronic HCV treated with PEG-IFNα-2b plus RBV.",
author = "Mosaburo Kainuma and Norihiro Furusyo and Murata Masayuki and Takeshi Ihara and Hiroaki Ikezaki and Kazuhiro Toyoda and Eiichi Ogawa and Kyoko Okada and Jun Hayashi",
year = "2013",
doi = "10.11339/jtm.30.132",
language = "English",
volume = "30",
pages = "132--139",
journal = "Journal of Traditional Medicines",
issn = "1880-1447",
publisher = "Medical and Pharmaceutical Society for WAKAN-YAKU",
number = "3",

}

TY - JOUR

T1 - The effectiveness of traditional Japanese medicine (Kampo), in combination with pegylated interferon α plus ribavirin for patients with chronic hepatitis C

T2 - A pilot study

AU - Kainuma, Mosaburo

AU - Furusyo, Norihiro

AU - Masayuki, Murata

AU - Ihara, Takeshi

AU - Ikezaki, Hiroaki

AU - Toyoda, Kazuhiro

AU - Ogawa, Eiichi

AU - Okada, Kyoko

AU - Hayashi, Jun

PY - 2013

Y1 - 2013

N2 - Background: Kampo medicine has been shown to be useful for reducing the adverse effects of pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV). The study was done to determine if Kampo would have a synergistic effect with PEG-IFNα-2b plus RBV that would improve their effectiveness in the treatment of chronic hepatitis C. Methods: From a total of 51 chronic hepatitis C virus (HCV) patients, 26 received PEG-IFNα-2b plus RBV treatment combined with Kampo medicine (group A) and 25 received only the standard treatment (group B). Group B patients were prescribed a mixture of shimbuto and ninjinto extract to be taken three times a day before meals. Results: The early virological response (EVR) and sustained virological response (SVR) rates were significantly higher in group A than in group B (EVR: 84.6%, 22 of 26 vs 56.0%, 14 of 25, P=0.034: SVR: 76.9%, 20 of 26 vs 48.0%, 12 of 25, P=0.033). 22 of 26 patients in group A (84.6%) and 18 of 25 patients in group B (72.0%) received at least the minimum acceptable dosage (at least 80% or more of the target PEG-IFNα-2b and 60% or more of RBV) during treatment, with no significant between group difference in the rate of SVR. The discontinuation rate was significantly lower in group A, in which no patients discontinued, than in group B (20.0%, 5 of 25) (P=0.023). Conclusions: A mixture of shimbuto and ninjinto reduced the discontinuation rate and improved the treatment efficacy of patients with chronic HCV treated with PEG-IFNα-2b plus RBV.

AB - Background: Kampo medicine has been shown to be useful for reducing the adverse effects of pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV). The study was done to determine if Kampo would have a synergistic effect with PEG-IFNα-2b plus RBV that would improve their effectiveness in the treatment of chronic hepatitis C. Methods: From a total of 51 chronic hepatitis C virus (HCV) patients, 26 received PEG-IFNα-2b plus RBV treatment combined with Kampo medicine (group A) and 25 received only the standard treatment (group B). Group B patients were prescribed a mixture of shimbuto and ninjinto extract to be taken three times a day before meals. Results: The early virological response (EVR) and sustained virological response (SVR) rates were significantly higher in group A than in group B (EVR: 84.6%, 22 of 26 vs 56.0%, 14 of 25, P=0.034: SVR: 76.9%, 20 of 26 vs 48.0%, 12 of 25, P=0.033). 22 of 26 patients in group A (84.6%) and 18 of 25 patients in group B (72.0%) received at least the minimum acceptable dosage (at least 80% or more of the target PEG-IFNα-2b and 60% or more of RBV) during treatment, with no significant between group difference in the rate of SVR. The discontinuation rate was significantly lower in group A, in which no patients discontinued, than in group B (20.0%, 5 of 25) (P=0.023). Conclusions: A mixture of shimbuto and ninjinto reduced the discontinuation rate and improved the treatment efficacy of patients with chronic HCV treated with PEG-IFNα-2b plus RBV.

UR - http://www.scopus.com/inward/record.url?scp=85024471699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024471699&partnerID=8YFLogxK

U2 - 10.11339/jtm.30.132

DO - 10.11339/jtm.30.132

M3 - Article

VL - 30

SP - 132

EP - 139

JO - Journal of Traditional Medicines

JF - Journal of Traditional Medicines

SN - 1880-1447

IS - 3

ER -